FDA pharmacologic class
Cytochrome P450 3A Inhibitor
2 medicines are in FDA's class of cytochrome p450 3a inhibitors: ritonavir (Norvir) and cobicistat (Tybost); 6 combination products also contain one. 2 of the 8 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is ritonavir 100 mg tablet at $0.607 per tablet (NADAC).
Which medicines are cytochrome p450 3a inhibitor?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Ritonavir | Norvir | 7 labelers | $0.607 per tablet 100 mg tablet | Yes | A presentation being discontinued | 1 |
| Lopinavir and ritonavir | Kaletra | 3 labelers | $4.46 per tablet 200-50 mg tablet | No | A presentation being discontinued | 0 |
| Cobicistat and darunavir | Prezcobix | none listed | $79.99 per tablet 800 mg-150 mg tablet | No | No current entry | 0 |
| Atazanavir and cobicistat | Evotaz | none listed | $52.05 per tablet 300 mg-150 mg tablet | No | A presentation being discontinued | 0 |
| Cobicistat | Tybost | none listed | n/a | No | A presentation being discontinued | 0 |
| Cobicistat, darunavir, emtricitabine and tenofovir alafenamide | Symtuza | none listed | $152.87 per tablet 800-150-200-10 mg tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Genvoya | none listed | $143.35 per tablet Genvoya tablet | Yes | No current entry | 0 |
| Cobicistat, elvitegravir, emtricitabine and tenofovir disoproxil | Stribild | none listed | $150.14 per tablet Stribild tablet | Yes | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price